Active	Status	Sponsor type	Region	Phase	Filter
1 Active 0 Inactive 1 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
ritivixibat (IPN60250) / Ipsen
NCT05642468: Safety and Tolerability of A3907 in Primary Sclerosing Cholangitis	Recruiting	2	24	Europe	Ritivixibat	Albireo, an Ipsen Company	Primary Sclerosing Cholangitis	06/25	06/25